.png){kind=small}
.png){kind=small}
BackTable / Tumor Board / Contributor
Dr. Lingling Du
Medical Oncologist
Dr. Lingling Du is an oncologist with Ochsner Health in New Orleans, Louisiana.
Listen to Dr. Lingling Du on the BackTable Tumor Board Podcast
The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Lingling Du and get practical advice on how to build your practice by listening to the BackTable Tumor Board Podcast.
Stay Up To Date
Follow:
Subscribe:
Sign Up:
About Dr. Lingling Du
Dr. Lingling Du specializes in medical oncology at Ochsner MD Anderson Cancer Center. She earned her medical degree from Peking University Health Science Center in China. She completed her internship and residency training at Cleveland Clinic Foundation. She completed fellowship training in hematology oncology at Washington University School of Medicine in St. Louis.Dr. Du specializes in hematology oncology and has a special interest in gastrointestinal cancers, including esophageal, gastric, liver, bile duct, pancreas, small bowel and colorectal cancers. She also specializes in treating gastrointestinal neuroendocrine tumors, a rare type of tumor. She is board-certified in internal medicine, hematology and medical oncology. Dr. Du believes every patient deserves the best care, and treatment should be highly individualized and personally tailored. She is also a strong supporter of multidisciplinary cancer care.
Podcasts Featuring Dr. Lingling Du
VI Episode #517
Treatment of hepatocellular carcinoma (HCC), like that of many other cancers, spans a spectrum from curative to palliative intent. To explore the "grey zone" of treatment goals for intermediate-stage HCC patients, Dr. Sabeen Dhand interviews a panel of experts in the field: medical oncologists Dr. Adam Burgoyne and Dr. Lingling Du, along with interventional radiologists Dr. Kirema Garcia-Reyes and Dr. Zachary Berman.
VI Episode #513
In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman.
Tumor Board Episode #5
Treatment of hepatocellular carcinoma (HCC), like that of many other cancers, spans a spectrum from curative to palliative intent. To explore the "grey zone" of treatment goals for intermediate-stage HCC patients, Dr. Sabeen Dhand interviews a panel of experts in the field: medical oncologists Dr. Adam Burgoyne and Dr. Lingling Du, along with interventional radiologists Dr. Kirema Garcia-Reyes and Dr. Zachary Berman.
Tumor Board Episode #3
In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman.
Get Connected
Thank you for listening! If you have a question for Dr. Lingling Du about a topic discussed on the BackTable Tumor Board Podcast, you can get in touch with this form. Please note that our contributors are not able to respond to every inquiry.
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Podcasts
Topics
More Contributors
Dr. Aparna Baheti
Dr. Michael Barraza
Dr. Pilar Bayona
Dr. Christopher Beck
Dr. George Behrens
Dr. Zach Berman